RESEARCH TRIANGLE PARK, N.C - Tuesday, September 17th 2013
Quintiles today announced that it has completed the previously
announced acquisition of Novella Clinical (Novella), a full-service
clinical research organization (CRO) focused primarily on emerging
oncology customers as well as those in the medical device and
diagnostics sectors.
“We are extremely pleased to have completed the acquisition of
Novella and look forward to working together to increase our
collective opportunities with emerging oncology and medical device
companies,” said Paula Brown Stafford, president, Clinical
Development at Quintiles. “With the transaction now officially
closed, we will focus our efforts on leveraging Quintiles’ global
resources and capabilities with the expertise and personal attention
of Novella to continue to deliver the high-quality services customers
have come to expect from both companies.”
Now known as “Novella Clinical, a Quintiles company,” Novella will
operate as a unit within Quintiles, retaining its existing leadership
team as well as its specialized customer focus.
About Quintiles
Quintiles (NYSE:Q) is the world’s largest provider of
biopharmaceutical development and commercial outsourcing services
with a network of more than 27,000 employees conducting business in
approximately 100 countries. We have helped develop or commercialize
all of the top-50 best-selling drugs on the market. Quintiles applies
the breadth and depth of our service offerings along with extensive
therapeutic, scientific and analytics expertise to help our customers
navigate an increasingly complex healthcare environment as they seek
to improve efficiency and effectiveness in the delivery of better
healthcare outcomes. To learn more about Quintiles, please visit
www.quintiles.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Such forward-looking
statements reflect, among other things, Quintiles’ current
expectations and anticipated results of operations, all of which are
subject to known and unknown risks, uncertainties and other factors
that may cause Quintiles’ actual results, performance or
achievements, market trends, or industry results to differ materially
from those expressed or implied by such forward-looking statements.
Therefore, any statements contained herein that are not statements of
historical fact may be forward-looking statements and should be
evaluated as such. Without limiting the foregoing, the words
“anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,”
“plans,” “projects,” “should,” “targets,” “will” and the negative
thereof and similar words and expressions are intended to identify
forward-looking statements.
These statements are subject to risks, uncertainties and assumptions,
including our ability to complete, integrate and achieve our intended
objectives with respect to the proposed acquisition of Novella
Clinical and those described under the section entitled "Risk
Factors" in Quintiles’ prospectus dated May 8, 2013, filed with the
SEC pursuant to Rule 424(b) of the Securities Act on May 9, 2013, as
such factors may be updated from time to time in Quintiles’ periodic
filings with the SEC, which are accessible on the SEC's website at
www.sec.gov. These factors should not be construed as exhaustive and
should be read in conjunction with the other cautionary statements
that are included in this release and in Quintiles’ filings with the
SEC. Unless legally required, Quintiles assumes no obligation to
update any such forward-looking information to reflect actual results
or changes in the factors affecting such forward-looking information.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Kevin Nash, 1-919-998-2514
Media Relations
kevin.nash@quintiles.com
Karl Deonanan, 1-919-998-2789
Investor Relations
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/8524/en
No comments:
Post a Comment